Personalized medicine: Lung Cancer leads the way

Indian Journal of Cancer

Volumn 50, Issue 2, 2013, Pages 77-79

  Parikh, Purvish ^a   Puri, T ^a  

^a Lung Cancer Consortium Asia ^*  (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; EGFR PROTEIN, HUMAN;

CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INCIDENCE; EDITORIAL; FINE NEEDLE ASPIRATION BIOPSY; GENE MUTATION; GENE SEQUENCE; HISTOLOGY; HUMAN; IMAGE GUIDED BIOPSY; INDIAN; LUNG ADENOCARCINOMA; LUNG BIOPSY; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG TUBERCULOSIS; METASTASIS; PATIENT ADVOCACY; PERSONALIZED MEDICINE; POLYMERASE CHAIN REACTION; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; SMOKING; SYSTEMATIC REVIEW (TOPIC); CARCINOMA, NON-SMALL-CELL LUNG; GENETICS; LUNG NEOPLASMS; PATHOLOGY;

CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; INDIVIDUALIZED MEDICINE; LUNG NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84884317465     PISSN: 0019509X     EISSN: 19984774     Source Type: Journal    
DOI: 10.4103/0019-509X.117005     Document Type: Editorial

References (19)

1. Parikh P, Chang AY, Nag S, Digumarti R, Bhattacharyya GS, Doval DC, et al. Clinical experience with gefitinib in Indian patients. J Thorac Oncol 2008;3: 380-5.
2. Veldore VH, Rao RM, Kakare S, Pattanayak S, Tejaswi R, Sahoo R, et al. EGFR mutation in NSCLC: A retrospective analysis of 1036 lung cancer specimens from a network of tertiary cancer care centers in India. Indian J Cancer 2013.
3. Bhat AD, Pai R, Rebekah R, Nehru GA, Dhananjayan S, Abraham S, et al. Clinicopathological features of non-small cell lung cancer in India and correlation with epidermal growth factor receptor [egfr] mutational status. Indian J Cancer 2013.
4. Mehta J. Molecular epidemiology of epidermal growth factor receptor mutations in lung cancers in Indian population. Indian J Cancer 2013.
5. Desai SS, Shah A, Prabhash K, Jambhekar NA. A year of anaplastic large cell kinase testing for lung carcinoma: Pathological and technical perspectives. Indian J Cancer 2013.
6. Choughule A, Noronha V, Joshi A, Dutt A, Desai S, Utture S, et al. EGFR mutation and its subtypes in Indian population: A study from single academic centre. Indian J Cancer 2013.
7. Prasad N, Bakshi A, Deshmukh C, Hingmire S, Ranade AA, Parikh P. Importance of dose intensity in treatment of advanced non-small cell lung cancer in the elderly. South Asian J Cancer, 2012;1: 9-15.
8. Bhatt ML, Kant S, Bhaskar R. Pulmonary tuberculosis as differential diagnosis of lung cancer. South Asian J Cancer 2012;1: 36-42.
9. Hirsch FR, Varella-Garcia M, Bunn PA Jr, Franklin WA, Dziadziuszko R, Thatcher N, et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 2006;24: 5034-42.
10. Parikh PM. Treatment of Lung Cancer in the Elderly. Ind J Med and Pead Oncol 1999;2: 140-7.
11. Parikh PM, Vaid A, Advani SH, Digumarti R, Madhavan J, Nag S, et al. Randomized, double-blind, placebo-controlled phase ii study of single-agent oral talactoferrin in patients with locally advanced or metastatic non-small-cell lung cancer that progressed after chemotherapy. J Clin Oncol 2011;29: 4129-36.
12. Louis RA, Rajendranath R, Ganesan P, Sagar TG, Krishnamurthy A. First report of upfront treatment with Gefitinib in comparison with chemotherapy in advanced non-small cell lung cancer patients from south India: Analysis of 120 patients. Indian J Med Paediatr Oncol. 2012;33: 146-54.
13. Chang A, Parikh P, Thongprasert S, Tan EH, Perng RP, Ganzon D, et al. Gefitinib (IRESSA) in patients of Asian origin with refactory advanced non-small-cell lung cancer: Subset analysis from the ISEL study. J Thorac Oncol 2006;1: 847-55.
14. Sahoo R, Harini VV, Babu VC, Patil Okaly GV, Rao S, Nargund A, et al. Screening for EGFR mutations in lung cancer, a report from India. Lung Cancer. 2011;73: 316-9.
15. Jiwnani S, Karimundackal G, Pramesh CS, Prabhash K. What is the true prevalence of EGFR mutations in India? Lung Cancer 2011;74:549.
16. Noronha V, Prabhash K, Thavamani A, Chougule A, Purandare N, Joshi A, et al. EGFR mutations in Indian lung cancer patients: Clinical correlation and outcome to EGFR targeted therapy. PLoS One 2013;8:e61561.
17. Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005;366: 1527-37.
18. Behera D Balamugesh T. Lung cancer in India. Indian J Chest Dis Allied Sci 2004;46: 269-81.
19. Noronha V, Dikshit R, Raut N, Joshi A, Pramesh CS, George K, et al. Epidemiology of lung cancer in India: Focus on the differences between non-smokers and smokers: A single-centre experience. Indian J Cancer 2012;49: 74-81.